Results 41 to 50 of about 114,702 (262)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Metabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Haematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat, Jules Russick, Bagirath Gangadharan, Julie Rayes, Mathieu Ing, Jan Voorberg, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +7 more
doaj   +1 more source

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting.
Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E. Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K. Aktas, Clive S. Zent, Ilan Goldenberg   +10 more
doaj   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee   +41 more
core   +2 more sources

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Journal of Pharmacology and Experimental Therapeutics, 2017
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.
T. Barf, T. Covey, R. Izumi, Bas van de Kar, Michael Gulrajani, B. van Lith, M. van Hoek, E. de Zwart, D. Mittag, Dennis Demont, S. Verkaik, Fanny Krantz, P. Pearson, R. Ulrich, A. Kaptein   +14 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis

Journal of Multiple Sclerosis and Neuroimmunology, 2023
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by controlling immune cell activity in the peripheral blood or inhibiting their migration from the periphery into the CNS. However,
Je-Young Shin, Suk-Won Ahn
openaire   +1 more source

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]

, 2015
We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén, Bezares, Raimundo F., Borge, Mercedes, Cabrejo, María, Colado, Ana, Fernández Grecco, Horacio, Gamberale, Romina, Giordano, Mirta Nilda, Podaza, Enrique Arturo   +8 more
core   +2 more sources

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma

CNS Oncology, 2020
The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment ...
Justin T Low, Katherine B Peters
doaj   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2016
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core   +1 more source